Conducted on a small sample of 21 patients with glioblastoma multiforme (GBM), a form of brain tumor that leaves its victims with less than 15 months to live. The study gave a group of patients tetrahydrocannabinol (THC) and cannabidiol (CBD) in addition to their other therapies, while the rest of the group was given a placebo.
There was an 83 percent survival rate of a year for those who took THC and CBD, and a 53 percent survival rate of a year for those given the placebo. This shows great promise in the development of a drug from the cannabis plant that could extend the lives of those with GBM and potentially other forms of brain cancer.
GW’s Chief Executive Officer Justin Gover stated, “We believe that the signals of efficacy demonstrated in this study further reinforce the potential role of cannabinoids in the field of oncology and provide GW with the prospect of a new and distinct cannabinoid product candidate in the treatment of glioma.”
This study furthers the scientific and anecdotal evidence that cannabis helps not only to treat the symptoms of cancer but heal cancer itself.
Shasta Nelson is a California Native and a cannabis connoisseur. She's been involved in the industry at every level since she was a teenager. Currently she provides content for Roottie, DOPE Magazine, and Terpenes and Testing. She's also a creative writer, with a graphic novel underway.